.svg){kind=small}
Oct-2026
Sales
Trend
6-Month
Product Count
SKUs
Avg Price
YoY Sales Change
YoY Price Change
Is this your brand?
See your full sales and distribution data: where you sell, how you're priced, and how you rank against the brands next to you on the shelf.
See your brand's dataCarry this brand in your store?
Headset Retailer is free. Connect your POS and see what's selling and what's sitting.
Sign up freeWhere to Buy
Breez is stocked at 263 licensed dispensaries across California and Illinois, 201 of them in California, with the deepest coverage in Los Angeles, San Diego, La Mesa, San Francisco, and Santa Rosa. Search by ZIP code or city below to find the closest one, or filter by product type if you are after a specific format.
Market Insights Snapshot
In October 2026, Breez concentrated 85.91% share in Capsules with year-over-year at -21.51% and month-over-month at -2.31%, while Edible held 7.51% share with -15.44% YoY and -11.77% MoM, and Tincture & Sublingual at 5.26% share posted -16.15% YoY and -18.85% MoM. Vapor Pens remained only 1.32% of sales yet spiked 168.34% MoM against a steep -64.51% YoY, indicating a tactical rebound from a low base. With brand-level sales down -22.10% YoY and average price edging -0.24% YoY to $38.12, the mix skews heavily toward Capsules at a time when all legacy formats are contracting, implying short-term revenue sensitivity to a single category despite a nascent test in Vapor Pens.
Breez’s second-place rank in Capsules in California positions the brand to defend core share even as Capsules contracted -21.51% YoY and -2.31% MoM, but the 168.34% MoM surge in Vapor Pens suggests headroom to diversify away from a 85.91% Capsules dependency. The sharper MoM declines in Edible (-11.77%) and Tincture & Sublingual (-18.85%) versus the milder Capsules pullback imply near-term allocation should prioritize Capsules to stabilize volume while selectively scaling Vapor Pens to capture incremental buyers, since the YoY drag of -64.51% in that format leaves room for recovery without cannibalizing the core.
Competitive Landscape
Breez sits at rank #2 in California Capsules in October 2026, unchanged year over year at #2, with a prior peak of #1 in June 2026 and a flat three-month position at #2; meanwhile, Emerald Bay Extracts climbed from #6 to #1 alongside a 171.8% YoY sales gain, and Level slid from #1 to #3 with a -43.1% YoY decline, indicating Breez is stable but being boxed out of leadership by an accelerating top rival while also not capitalizing on a weakening competitor — a pattern implying Breez’s rank is durable yet vulnerable to further erosion without a catalyst to reclaim #1.
Notable Products
Breez’s sales in October 2026 are tightly concentrated in capsule tablets, with the top three 50-pack Extra Strength variants accounting for 75.9% of brand sales and the top 10 items reaching 88.8%. The Indica Extra Strength Tablet 50-Pack alone holds 28.1%, so most of its sales ride on a small set of capsule SKUs.
Peer avg: average price of the same product type and package size in the same states that month.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
